Related Experiment Video
Updated: Aug 30, 2026

An In Vivo Estrogen Deficiency Mouse Model for Screening Exogenous Estrogen Treatments of Cardiovascular Dysfunction After Menopause
Published on: August 13, 2019
[Hormonal replacement therapy in menopause and cancer risk. An update]
1Istituto di Ricerche Farmacologiche, Mario Negri, Milano, Italy. lavecchia@marionegri.it
Abstract:
The risk of breast cancer rises by about 2.3% per year of using estrogens and the risk is even higher in the case of combined therapy with estrogens and progestins; however the excess risk disappears 5 years after suspension of the treatment. The risk of endometrial tumour cancer is strongly associated with the use of estrogens but this increase is reduced or eliminated by the administration of progestinics for at least 12/14 days per month. The use of HRTs also seems to be directly associated with the risk of ovarian cancers, while they seem to exert a protective effect on colorectal neoplasms. The HRTs has favourable effects on bone metabolims, but they increase the risk of deep venous thrombosis and pulmonary embolism.
Related Concept Videos
Menopause
Hormonal Regulation of the Menstrual Cycle
At puberty, GnRH begins a pulsatile release pattern, which triggers the anterior pituitary gland to secrete follicle-stimulating hormone (FSH) and luteinizing hormone (LH). The frequency and amplitude of GnRH pulses vary across the menstrual cycle, with faster pulses favoring LH release and slower pulses favoring FSH release.
Hormonal Control of the Ovarian Cycle
Before puberty, the hypothalamus releases GnRH in a low frequency, low amplitude pulsatile manner. This along with the immature hypothalamic-pituitary-gonadal axis activity, results in low estrogen levels and the absence of a fully functional ovarian cycle. At puberty, GnRH secretion increases in both frequency and...
Hormonal Regulation
Hormonal Regulation
Disorders of the Female Reproductive System
